It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hyponatremia on admission has been related to worse outcomes in patients with COVID-19 infection. However, little is known about the frequency and the associated risk factors of hyponatremia after COVID-19 discharge. We performed an observational 24-month follow-up study of patients admitted during the first COVID-19 wave. Kaplan–Meier curves and Cox proportional hazard models were used to assess the main variables in predicting hyponatremia on follow-up (HYPO-FU). A total of 161 out of 683 (24.4%) developed HYPO-FU. The group with HYPO-FU comprised of more men [(62.3%) vs. (49.2%); p < 0.01], older [65.6 ± 18.2 vs. 60.3 ± 17.0; p < 0.01] and more frequently re-admitted [(16.2%) vs. (3.8%); p < 0.01). The rate of HYPO-FU was higher in the first year 23.6 per 100 individuals per year. After Cox regression analysis, the independent risk factors of HYPO-FU were diabetes [OR 2.12, IC 95% (1.48–3.04)], hypertension [OR 2.18, IC 95% (1.53–3.12)], heart failure [OR 3.34, IC 95% (1.72–6.48)] and invasive ventilation support requirement [OR: 2.38, IC 95% (1.63–3.50)]. To conclude, HYPO-FU was frequent in the first year after COVID-19 infection, and the risk was higher in older men with comorbidities, increasing rehospitalisation. Further studies aimed at evaluating the beneficial effects of correcting hyponatremia in these patients are warranted.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Universidad Autónoma de Barcelona, Endocrinology Department, Diabetes and Metabolism Research Unit, Vall d’Hebron University Hospital and Vall d’Hebron Research Institute (VHIR), Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625)
2 Universitat Autònoma de Barcelona, Infectious Diseases Department, Vall d’Hebrón University Hospital, Global Health Program from the Catalan Health Institute (PROSICS), Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Mycobacterial Infection Study Group from the Spanish Society of Clinical Microbiology and Infectious Diseases (GEIM-SEIMC), Barcelona, Spain (GRID:grid.7080.f); Instituto de Salud Carlos III, Infectious Diseases Netword Biomedical Research Center (CIBERINFEC), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
3 Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Liver Unit, Vall d’Hebron Hospital Universitari, Vall d’Hebron Institut of Research (VHIR), Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)
4 Autonomous University of Barcelona (UAB), Pneumology Department, Vall d’Hebron University Hospital, Department of Medicine, Barcelona, Spain (GRID:grid.7080.f) (ISNI:0000 0001 2296 0625); Vall d’Hebron Research Institute (VHIR), Barcelona, Spain (GRID:grid.430994.3) (ISNI:0000 0004 1763 0287)
5 Vall d’Hebron University Hospital, Vall d’Hebron Barcelona Hospital Campus, Department of Clinical Pharmacology, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
6 Vall d’Hebron Barcelona Hospital Campus, Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)
7 Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Pharmacy Department, Barcelona, Spain (GRID:grid.411083.f) (ISNI:0000 0001 0675 8654)